Therapy for fungal diseases: opportunities and priorities.
about
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal diseaseMolecular mechanisms of cryptococcal meningitisCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsAdvances in the treatment of invasive neonatal candidiasisGenetic and structural validation ofAspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase as an antifungal targetHigh-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal ErgolinesCombination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisNovel antifungal agents: a patent review (2013 - present).Cryptococcal meningitis: epidemiology and therapeutic options.Caenorhabditis elegans-based model systems for antifungal drug discovery.A Nonredundant Phosphopantetheinyl Transferase, PptA, Is a Novel Antifungal Target That Directs Secondary Metabolite, Siderophore, and Lysine Biosynthesis in Aspergillus fumigatus and Is Critical for Pathogenicity.Endoplasmic reticulum localized PerA is required for cell wall integrity, azole drug resistance, and virulence in Aspergillus fumigatus.Evaluation of lysine biosynthesis as an antifungal drug target: biochemical characterization of Aspergillus fumigatus homocitrate synthase and virulence studiesThe Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosisA case-control study of risk factors for HIV-negative children with cryptococcal meningitis in Shi Jiazhuang, China.Analytical chemistry: Virulence caught green-handed.Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyIdentification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal moleculesDifferentiation of the emerging human pathogens Trichosporon asahii and Trichosporon asteroides from other pathogenic yeasts and moulds by using species-specific monoclonal antibodies.Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Azole drug import into the pathogenic fungus Aspergillus fumigatus.Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesisDrug-induced hypersensitivity syndrome by liposomal amphotericin-B: a case report.Exploring the molecular basis of antifungal synergies using genome-wide approaches.The RAM network in pathogenic fungi.Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.Antibacterial and antifungal potentials of the solvents extracts from Eryngium caeruleum, Notholirion thomsonianum and Allium consanguineumNeutrophil Interactions Stimulate Evasive Hyphal Branching by Aspergillus fumigatus.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensMultiplexed activity-based protein profiling of the human pathogen Aspergillus fumigatus reveals large functional changes upon exposure to human serumCoordination of hypoxia adaptation and iron homeostasis in human pathogenic fungi.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisPharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.Genome-Wide Expression Profiling Reveals S100B as Biomarker for Invasive Aspergillosis.Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.Software for dosage individualization of voriconazole for immunocompromised patientsPharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
P2860
Q24628838-B634FF2A-5C06-484D-A3C3-D6E6E83C99E3Q24632155-480E1BA7-24E9-45C2-84A6-47FE4DCFF804Q26863344-A5D7B7C1-ECEE-42C3-BADD-216D228E6C89Q27022585-1E374145-0905-4F07-836F-3763D0988DC7Q27678557-3E98F088-422A-4280-8F6F-4CDB2CE68BE4Q28554843-7E9E85A4-ACFF-40D9-B02B-26DC44804333Q28727508-6B3815D2-169B-4541-B347-C6FB271B9691Q30239745-7DE84CBF-BC63-4D3E-8098-948E37BFEB56Q33633343-2AC8847B-AEBC-415E-98D9-AEA6A3EF2321Q33864072-44E45CC8-4010-4E28-8127-446BC4568147Q33916498-BE1E9A0C-0419-460A-9330-E74841FD6D8AQ33956119-95F9B188-3ADF-41E3-BEC4-4835F8AA68F4Q33983108-2B66CB05-13CB-42BA-930B-A8CCE20100F9Q34426797-62C6243C-D10F-4DC4-A259-D5CE730C5D83Q34456015-AACDF223-B21A-4FCB-AFF7-FB2FBCF58678Q34522791-DE33419C-7378-4393-A8C6-984E4461DB1BQ34592066-32002799-E7D5-41B0-BC6E-2A48E22D76BAQ34754956-9F296AD2-BE8A-4538-B5EC-750712D9E491Q34995642-E9BAC661-AF84-46AB-BCDA-60D1C885C6B6Q35083471-9C22DE70-450E-44C2-A89A-BA849069F9BCQ35270948-6AADE529-8597-4E1A-BEE2-D9059FD1B39AQ35385786-9A495DE4-DD2C-40FB-90B1-4F53620E799BQ35607733-157E7182-9528-48E1-88C6-8405A2477260Q35666165-9481233B-708D-4B5F-B49B-A2142B683DD8Q35689250-38980F00-EA5B-4CFD-89B3-06D58C6FEDEDQ35792845-39B69744-F6ED-401C-9323-4D45674DAF7DQ35854979-60E26333-6CD1-4F5B-AA2F-447D4CE2284EQ36017845-C5497EDB-7E23-451E-8190-33E9E5F60AF3Q36171643-97E94E42-1749-421B-8784-CDE389157B7BQ36202947-46866426-D7ED-462B-B0EE-A89EEE2CE6D5Q36246329-2C0EC5F1-62F7-49B2-A431-C1B180B2F33BQ36276870-0A5AFDBB-2EEE-4CD8-A184-1D1EDDC44F19Q36286132-F291B2E1-AEBC-4911-86F1-2750643A60A6Q36374709-828BFFF5-B370-48A3-B39E-D235E6C50321Q36439102-24751881-9D0D-4E1B-9126-D2DC339597D6Q36505301-5B6A7DCF-B4E5-4FB8-B420-DBD6B9E3AC0EQ36707560-5FC4645A-233D-43A6-BA16-472264BE0F47Q36730105-97B7F1F7-76AB-4B09-9DE3-DF7990AA2202Q36757595-B173EE30-F84A-4639-8B9F-99EDC36C3064Q36936353-4ED2FB42-E51D-4B9D-B854-82A1817AF6C5
P2860
Therapy for fungal diseases: opportunities and priorities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy for fungal diseases: opportunities and priorities.
@en
Therapy for fungal diseases: opportunities and priorities.
@nl
type
label
Therapy for fungal diseases: opportunities and priorities.
@en
Therapy for fungal diseases: opportunities and priorities.
@nl
prefLabel
Therapy for fungal diseases: opportunities and priorities.
@en
Therapy for fungal diseases: opportunities and priorities.
@nl
P1476
Therapy for fungal diseases: opportunities and priorities.
@en
P304
P356
10.1016/J.TIM.2010.02.004
P577
2010-03-06T00:00:00Z